Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence
Crossref DOI link: https://doi.org/10.1007/s40273-016-0418-8
Published Online: 2016-06-08
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Llewellyn, Alexis
Faria, Rita
Woods, Beth
Simmonds, Mark
Lomas, James
Woolacott, Nerys
Griffin, Susan
Funding for this research was provided by:
Health Technology Assessment Programme (14/148/01)
License valid from 2016-06-08